Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(37 sites)

United States

Usc Norris Comprehensive Cancer Center, Los Angeles, California

Northwestern Medicine, Chicago, Illinois

Memorial Sloan Kettering Cancer Center, New York, New York

Duke University, Durham, North Carolina

Gibbs Cancer Center, Spartanburg, South Carolina

Tennesse Oncology - Elliston Place Plaza, Nashville, Tennessee

The University of Texas Md Anderson Cancer Center, Houston, Texas

Australia

Alfred Health, Melbourne

Brazil

Hospital de Amor - Barretos, Barretos

Oncoclinicas Mg, Belo Horizonte

CIONC, Curitiba

Instituto Dor de Pesquisa E Ensino Sp, São Paulo